A Randomized Controlled Multicenter US Food and Drug Administration Trial of the Safety and Efficacy of the Minerva Endometrial Ablation System: One-Year Follow-Up Results

AbstractStudy ObjectiveTo assess the safety and effectiveness of the Minerva Endometrial Ablation System for the treatment of heavy menstrual bleeding in premenopausal women.DesignMulticenter, randomized, controlled, international study (Canadian Task Force classification I).SettingThirteen academic and private medical centers.PatientsPremenopausal women (n = 153) suffering from heavy menstrual bleeding (PALM-COEIN: E, O).InterventionPatients were treated using the Minerva Endometrial Ablation System or rollerball ablation.Measurements and Main ResultsAt 1-year post-treatment, study success (alkaline hematin ≤80 mL) was observed in 93.1% of Minerva subjects and 80.4% of rollerball subjects with amenorrhea reported by 71.6% and 49% of subjects, respectively. The mean procedure times were 3.1 minutes for Minerva and 17.2 minutes for rollerball. There were no intraoperative adverse events and/or complications reported.ConclusionThe results of this multicenter randomized controlled trial demonstrate that at the 12-month follow-up, the Minerva procedure produces statistically significantly higher rates of success, amenorrhea, and patient satisfaction as well as a shorter procedure time when compared with the historic criterion standard of rollerball ablation. Safety results were excellent and similar for both procedures